Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors could potentially alter calcium and phosphate homeostasis and may increase the risk of bone fracture.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Diabetes Metab. Res. Rev.

Title: Diabetes/metabolism research and reviews

Publisher: Wiley-Blackwell

ISSN (Electronic): 1520-7560

ISSN (Print): 1520-7552

Publication date (Electronic): Sep 2017

Volume: 33

Issue: 6

Affiliations

[1 ] Department of Medicine, University of Minnesota, Minneapolis, MN, USA.

[2 ] Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.

[3 ] Division of Diabetes and Endocrinology, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.

Article

DOI: 10.1002/dmrr.2903

PubMed ID: 28440590

SO-VID: 7ade752e-eeb8-4535-8200-13271afc36da

History

Keywords: SGLT2 inhibitor,fracture,type 2 diabetes

Data availability:

Keywords: SGLT2 inhibitor, fracture, type 2 diabetes

Comments

Comment on this article

scite_

Cited by 50

See all cited by